End-of-day quote
Hong Kong S.E.
03:30:00 21/06/2024 am IST
|
5-day change
|
1st Jan Change
|
17.94
USD
|
+1.36%
|
|
+9.66%
|
-43.94%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
34,275
|
20,143
|
-
|
-
|
Enterprise Value (EV)
1 |
30,230
|
16,776
|
16,943
|
16,550
|
P/E ratio
|
112
x
|
34.2
x
|
21.6
x
|
14.9
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
16.1
x
|
6.37
x
|
4.37
x
|
3.17
x
|
EV / Revenue
|
14.2
x
|
5.31
x
|
3.67
x
|
2.61
x
|
EV / EBITDA
|
81.2
x
|
21.1
x
|
13.6
x
|
9.28
x
|
EV / FCF
|
-154
x
|
-19.3
x
|
-355
x
|
33.6
x
|
FCF Yield
|
-0.65%
|
-5.19%
|
-0.28%
|
2.98%
|
Price to Book
|
6.39
x
|
3.35
x
|
2.9
x
|
2.42
x
|
Nbr of stocks (in thousands)
|
11,78,446
|
11,97,604
|
-
|
-
|
Reference price
2 |
29.09
|
16.69
|
16.69
|
16.69
|
Announcement Date
|
25/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
2,124
|
3,160
|
4,614
|
6,351
|
EBITDA
1 |
-
|
372.5
|
793.3
|
1,249
|
1,784
|
EBIT
1 |
-
|
343.5
|
661.1
|
1,067
|
1,568
|
Operating Margin
|
-
|
16.17%
|
20.92%
|
23.12%
|
24.69%
|
Earnings before Tax (EBT)
1 |
-
|
359.6
|
710
|
1,123
|
1,628
|
Net income
1 |
155.7
|
283.5
|
575.5
|
918.3
|
1,335
|
Net margin
|
-
|
13.35%
|
18.21%
|
19.9%
|
21.02%
|
EPS
2 |
0.1800
|
0.2600
|
0.4873
|
0.7726
|
1.119
|
Free Cash Flow
1 |
-
|
-196.5
|
-870.7
|
-47.67
|
493
|
FCF margin
|
-
|
-9.25%
|
-27.55%
|
-1.03%
|
7.76%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
27.63%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
36.93%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/11/23
|
25/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
1,130
|
1,392
|
1,702
|
EBITDA
|
-
|
-
|
-
|
EBIT
1 |
192.4
|
337.6
|
423.4
|
Operating Margin
|
17.02%
|
24.25%
|
24.88%
|
Earnings before Tax (EBT)
|
148
|
-
|
-
|
Net income
|
106.3
|
-
|
-
|
Net margin
|
9.41%
|
-
|
-
|
EPS
|
0.0800
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
25/03/24
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
4,045
|
3,367
|
3,201
|
3,593
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-197
|
-871
|
-47.7
|
493
|
ROE (net income / shareholders' equity)
|
-
|
8.18%
|
10.2%
|
14.2%
|
17.5%
|
ROA (Net income/ Total Assets)
|
-
|
6.14%
|
9.45%
|
12%
|
15%
|
Assets
1 |
-
|
4,616
|
6,089
|
7,671
|
8,917
|
Book Value Per Share
2 |
-
|
4.550
|
4.980
|
5.750
|
6.890
|
Cash Flow per Share
2 |
-
|
0.3100
|
0.6000
|
0.8100
|
1.220
|
Capex
1 |
-
|
529
|
1,546
|
958
|
471
|
Capex / Sales
|
-
|
24.92%
|
48.92%
|
20.76%
|
7.41%
|
Announcement Date
|
06/11/23
|
25/03/24
|
-
|
-
|
-
|
Last Close Price
16.69
CNY Average target price
28.8
CNY Spread / Average Target +72.54% Consensus |
1st Jan change
|
Capi.
|
---|
| -43.94% | 2.75B | | +51.63% | 796B | | +40.83% | 628B | | -5.10% | 358B | | +19.90% | 331B | | +9.95% | 301B | | +17.36% | 244B | | +4.01% | 228B | | +12.83% | 214B | | +6.99% | 165B |
Other Pharmaceuticals
|